Clinical trials: Cryptogenic Stroke
Patent Foramen Ovale, Closure; Foramen Ovale
Residual Shunt After Patent Foramen Ovale Device Closure in Patients With Cryptogenic Stroke
Among consecutive 47 cryptogenic stroke patients who underwent PFO closure, a serial follow-up bubble contrast TEE at 3 and 9 months after the index procedure was completed in 38 patients (81%, 46±10 years, 19 men).
- Trial name
- NCT03416426
- Testing
- Amplatzer® PFO occluder or Gore® Septal Occluder
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Gachon University Gil Medical Center
Patent Foramen Ovale, Atrial Fibrillation
Prevalence of Atrial Fibrillation in Cryptogenic Stroke With Patent Foramen Ovale Closure (PFO-AF) Study
This study aims to assess the incidence of atrial fibrillation (AF), documented using data recorded by an implantable Holter monitoring device (Reveal Linq, Medtronic) within 2 years after percutaneous closure of patent foramen…
- Conditions
- Patent Foramen Ovale, Atrial Fibrillation, Stroke
- Trial name
- PFO-AF (NCT04926142)
- Testing
- Implantation of Holter device, Percutaneous PFO closure
- Where
- 4 sites in France
- Volunteers
- 250 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Patent Foramen Ovale, Cryptogenic Stroke
Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure
Patent foramen ovale PFO closure has been shown to reduce the risk of stroke in patients with recurrent stroke. However, the majority of existing clinical studies in this field excluded patients over the age of 60 years.
- Conditions
- Patent Foramen Ovale, Cryptogenic Stroke, Older Patients, Medical Treatment
- Trial name
- STOP (NCT05907694)
- Testing
- Transcatheter PFO closure, Optimal medical treatment
- Where
- 2 sites in Canada
- Volunteers
- 714 people
- Sponsor
- Josep Rodes-Cabau
Stroke, Atrial Fibrillation
Detection of Occult Paroxysmal Atrial Fibrillation After Stroke Using Prolonged Ambulatory Cardiac Monitoring
About one-third of patients with stroke have no documented cause for the cerebrovascular event (known as cryptogenic strokes). Atrial fibrillation is a common cause of stroke, but when transient (paroxysmal) it may remain…
- Trial name
- NCT01325545
- Testing
- Mobile cardiac rhythm monitoring
- Volunteers
- 132 people
- Sponsor
- Mayo Clinic
Embolic Stroke of Undetermined Source
AI-Based Prediction of Atrial Fibrillation in ESUS Patients With ICM
This study investigates patients with Embolic Stroke of Undetermined Source (ESUS) who have received an Implantable Cardiac Monitor (ICM).
- Trial name
- SMART-ESUS (NCT07347691)
- Where
- 5 sites in South Korea
- Volunteers
- 92 people
- Sponsor
- Inha University Hospital
Stroke, Stroke, Acute Ischemic
NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke
This is a randomized, controlled, open-label study of MLC901 (NeuroAiD™ II) in patients with mild to moderate ischemic stroke. Eligible participants will be randomized in a 1:1 ratio to receive MLC901 in combination with standard…
- Conditions
- Stroke, Stroke, Acute Ischemic, Stroke, Ischemic, Stroke, Cryptogenic
- Trial name
- NAiD-PRO (NCT07828210)
- Testing
- MLC901, Standard treatment for acute ischemic stroke
- Where
- Vietnam
- Volunteers
- 80 people
- Sponsor
- EVD Pharmacy and Medical Company Limited
Small Vessel Cerebrovascular Disease
Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial
Chronic damage to small blood vessels deep in the brain is seen in half of patients over the age of 60 and almost all patients over the age of 80, and is responsible for up to a third of strokes and almost half of patients with…
- Trial name
- OxHARP (NCT03855332)
- Testing
- Sildenafil, Cilostazol
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- University of Oxford
Patent Foramen Ovale, Cryptogenic Stroke
Long-term Outcomes After Percutaneous Patent Foramen Ovale Closure (Severance PFO Registry)
Patent foramen ovale (PFO) is a congenital interatrial communication present in about one quarter of the general population and is recognized as a major cause of cryptogenic stroke.
- Conditions
- Patent Foramen Ovale, Cryptogenic Stroke, Transient Ischemic Attack Due to Embolism, Atrial Fibrillation
- Trial name
- NCT07724171
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Yonsei University
Stroke
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified.
- Trial name
- NAVIGATE ESUS (NCT02313909)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036)
- Where
- 454 sites in United States, Argentina and 29 more
- Volunteers
- 7,213 people
- Sponsor
- Bayer
Cardiac Arrythmias, Syncope
Confirm Rx™ Versus Reveal LINQ™ - Which is More Reliable in Data Transmission? A Randomized Clinical Study
This study will compare the reliability and timeliness in data transmission of the Abbott Confirm Rx™ loop recorder with the Medtronic Reveal LINQ™ loop recorder.
- Conditions
- Cardiac Arrythmias, Syncope, Atrial Fibrillation, Atrial Flutter
- Trial name
- NCT03720639
- Testing
- Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM
- Where
- 2 sites in United States
- Volunteers
- 209 people
- Sponsor
- Sparrow Clinical Research Institute
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Stroke
Left Atrial Function in Recurrent Stroke of Unknown Cause
Stroke is an important cause of disability and the third leading cause of death. Approximately 30 to 40 % of all strokes are estimated to be cryptogenic (i.e. no cause can be found).
- Trial name
- NCT02968329
- Where
- Belgium
- Volunteers
- 500 people
- Sponsor
- Hasselt University
Stroke
Long-term Cardiac Monitoring After Cryptogenic Stroke (CMACS)
Atrial fibrillation (AF) is a common and treatable cause of ischemic stroke, but it can be paroxysmal and asymptomatic, and therefore difficult to detect.
- Trial name
- CMACS (NCT00932425)
- Testing
- Cardionet Mobile Cardiac Outpatient Telemetry (MCOT)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Cryptogenic Stroke, Atrial Fibrillation
Incidence and Predictors of Recurrent Stroke in Cryptogenic Stroke Patients With Atrial Fibrillation
Brief Summary: This study aimed to investigate the risk and factors that predict recurrent stroke in patients who initially had a stroke with no clear cause (called cryptogenic stroke) and were later found to have atrial…
- Conditions
- Cryptogenic Stroke, Atrial Fibrillation, Recurrent Ischemic Stroke
- Trial name
- NCT07126184
- Testing
- Extended Cardiac Monitoring
- Where
- Pakistan
- Volunteers
- 109 people
- Sponsor
- Nangarhar University
Idiopathic Toe Walking, Cerebral Palsy
The Effect of Targeting the Plantaris Muscle-tendon in Surgical Correction of Ankle Equinus in Children
Tight ankle muscles can produce ankle equinus (limited ability to pull the foot upward) and occur often in children, significantly impacting their ability to walk.
- Conditions
- Idiopathic Toe Walking, Cerebral Palsy, Hereditary Spastic Paraparesis, Traumatic Brain Injury
- Trial name
- Plantaris Sx (NCT07090057)
- Testing
- Tendoachilles (TA) lengthening or gastrocnemius (GN) recession, then Plantaris tenotomy, Plantaris tenotomy, then Tendoachilles (TA) lengthening or gastrocnemius (GN) recession
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- University of Alberta
Immune Thrombocytopenia (ITP), Acute Ischemic Stroke
Longitudinal Cohort Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke
Immune thrombocytopenia (ITP) is an acquired bleeding disorder mediated by immune-related platelet destruction and impaired platelet production.
- Trial name
- NCT07070193
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Ischemic Stroke
Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke
The purpose of this study is to determine the incidence of paroxysmal atrial fibrillation (AF) in ischemic stroke patients who have a presumed known stroke etiology other than atrial fibrillation.
- Trial name
- NCT02232022
- Testing
- Reveal LINQ Insertable Cardiac Monitor
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Northwell Health
Paroxysmal Atrial Fibrillation, Cardiac Rhythm Disorder
Atrial Anomalies Predict Silent Atrial Fibrillation Detected by Implantable Cardiac Monitor in Cryptogenic Stroke
Cryptogenic stroke (CS) causes about 30% of admissions to a stroke unit. Silent paroxysmal atrial fibrillation (PAF) is believed to be the underlying cause of a significant proportion of patients.
- Conditions
- Paroxysmal Atrial Fibrillation, Cardiac Rhythm Disorder, Left Atrial Dilatation, Cryptogenic Stroke
- Trial name
- CRIPTO-FAST (NCT06542770)
- Testing
- Early implant of cardiac monitor
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Parc de Salut Mar
Atrial Fibrillation, Ischemic Stroke
Atrial Fibrillation in Cryptogenic Stroke and TIA
Background: Different studies with real-life data and randomized controlled trials have shown a detection rate of paroxysmal atrial fibrillation (AF) of 10-20% in patients with cryptogenic stroke using insertable continuous…
- Conditions
- Atrial Fibrillation, Ischemic Stroke, TIA
- Trial name
- NOR-FIB (NCT02937077)
- Testing
- Medtronic Reveal LINQ
- Where
- 2 sites in Norway
- Volunteers
- 259 people
- Sponsor
- Oslo University Hospital
Atrial Fibrillation, Syncope
LUX-Dx Insertable Cardiac Monitor Remote Programming and Performance Study
The LUX-Dx PERFORM Study had two primary objects which were (1) to characterize, in a general patient population, the utilization of the remote programming feature of the Boston Scientific (BSC) Insertable Cardiac Monitor (ICM)…
- Conditions
- Atrial Fibrillation, Syncope, Cryptogenic Stroke
- Trial name
- LUX-Dx PERFORM (NCT04732728)
- Where
- 24 sites in United States
- Volunteers
- 727 people, healthy volunteers welcome
- Sponsor
- Boston Scientific Corporation